Flow cytometric phenotyping and analysis of T regulatory cells in multiple myeloma patients

Klinicka Onkologie

Volumn 24, Issue SUPPL., 2011, Pages

  Muthu Raja, K R ^a   Kovarova L ^a,b   Stossova J ^a   Hájek, Roman ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Flow cytometry; Multiple myeloma; Thalidomide; Tregs

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; THALIDOMIDE; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PHENOTYPE; REGULATORY T LYMPHOCYTE;

FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MULTIPLE MYELOMA; T-LYMPHOCYTES, REGULATORY;

EID: 79959935079     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kyle RA, Rajkumar SV Criteria for diagnosis staging risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23(1): 3-9.
2. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010; 149(3): 334-351.
3. Mills KH, Cawley JC Abnormal monoclonal antibody defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br J Haematol 1983; 53(2): 271-275. (Pubitemid 13171501)
4. Wolf AM, Wolf D, Steurer M et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9(2): 606-612. (Pubitemid 36182591)
5. Fehérvari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest 2004; 114(9): 1209-1217. (Pubitemid 40385288)
6. Bates GJ, Fox SB, Han C et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24(34): 5373-5380. (Pubitemid 46623168)
7. Beyer M, Kochanek M, Darabi K et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106(6): 2018-2025. (Pubitemid 41291715)
8. Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003; 15(4): 430-435. (Pubitemid 36774255)
9. Vieira PL, Christensen JR, Minaee S et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 2004; 172(10): 5986-5993. (Pubitemid 38621199)
10. Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198(12): 1875-1886. (Pubitemid 38032120)
11. Fischer K, Voelkl S, Heymann J et al. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4-CD8-double-negative regulatory T cells. Blood 2005; 105(7): 2828-2835. (Pubitemid 40446276)
12. Peng G, Wang HY, Peng W et al. Tumor-infiltrating gamma delta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway Immunity 2007; 27(2): 334-348.
13. Wang RF. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Hum Immunol 2008; 69(11): 811-814
14. Gil-Guerrero L, Dotor J, Huibregtse IL et al. In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta 1 J Immunol 2008; 181(1): 126-135.
15. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 2003; 3(5): 361-370. (Pubitemid 37323196)
16. Cao X. Regulatory T cells and immune tolerance to tumors. Immunol Res 2010; 46(1-3): 79-93.
17. Oderup C, Cederbom L, Makowska A et al. Cytotoxic T lymphocyte antigen-4 dependent down-modulation of costimulatory molecules on dendritic cells in CD4+CD25+ regulatory T-cell-mediated suppression. Immunology 2006; 118(2): 240-249. (Pubitemid 43727429)
18. Beyer M, Kochanek M, Giese T et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma Blood 2006; 107(10): 3940-3949.
19. Feyler S, von Lilienfeld-Toal M, Jarmin S et al. CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4-CD8-αβ TCR+ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 2009; 144(5): 686-695.
20. Prabhala RH, Neri P, Bae JE et al Dysfunctional T regulatory cells in multiple myeloma. Blood 2006; 107(1): 301-304. (Pubitemid 43053555)
21. Gupta R, Ganeshan P, Hakim M et al. Significantly reduced regulatory T cell population in patients with untreated multiple myeloma Leuk Res 2010. Epub of print.
22. Brimnes MK, Vangsted AJ, Knudsen LM et al. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR-/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 2010; 72(6): 540-547.
23. Atanackovic D, Cao Y, Luetkens T et al. CD4+CD25+-FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica 2008; 93(3): 423-430 (Pubitemid 351398644)
24. Wang X, Zheng J, Liu J et al. Increased population of CD4 (+) CD25 (high) regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol 2005; 75(6): 468-476. (Pubitemid 41687780)
25. Yang ZZ, Novak AJ, Stenson MJ et al. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T-cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107(9): 3639-3646.
26. Giannopoulos K, Schmitt M, Własiuk P et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 2008; 22(1): 222-224.
27. Quach H, Ritchie D, Stewart AK et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24(1): 22-32.